大葉大學圖書館 |

登入

回首頁

1. Capital Market Returns to New Pro...

Park, Kyung Mi.

1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
書名/作者:	1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs.
作者:	Park, Kyung Mi.
面頁冊數:	127 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-03(E), Section: A.
Contained By:	Dissertation Abstracts International77-03A(E).
標題:	Marketing.
標題:	Economics.
標題:	Finance.
ISBN:	9781339231228
摘要、提要註:	[Essay 1].
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3734510

1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs.
Park, Kyung Mi.

1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs. - 127 p.

Source: Dissertation Abstracts International, Volume: 77-03(E), Section: A.

Thesis (Ph.D.)--Purdue University, 2015.

[Essay 1].

ISBN: 9781339231228Subjects--Topical Terms:

173043
Marketing.

1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs.
LDR:03935nam a2200325 4500 001 441017
005 20160422125048.5
008 160525s2015 ||||||||||||||||| ||eng d
020 $a 9781339231228
035 $a (MiAaPQ)AAI3734510
035 $a AAI3734510
040 $a MiAaPQ $c MiAaPQ
100 1 $a Park, Kyung Mi. $3 630096
245 1 0 $a 1. Capital Market Returns to New Product Development Success: Informational Effects on Product Market Advertising 2. On the Expected Success Likelihood of New Drug Development and the Design of New Drug Market Launch Programs.
300 $a 127 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-03(E), Section: A.
500 $a Adviser: Manohar U. Kalwani.
502 $a Thesis (Ph.D.)--Purdue University, 2015.
520 $a [Essay 1].
520 $a I seek to answer the question: If the capital market reacts with abnormal stock returns to new product development success events, do these returns influence subsequent marketing decisions? Drawing on price informativeness and managerial learning theories, I posit that when firms are uncertain about how responsive the product market will be to their marketing activities, signals received from the capital market help them update their beliefs about the responsiveness. After decomposing the abnormal returns at the new drug approval event into components that can and cannot be predicted by the firm (i.e., predicted and unpredicted abnormal returns), I find that the post-approval advertising budget is larger when unpredicted abnormal approval returns are higher. Further, this tendency is more pronounced for detailing spending than for direct-to-consumer (DTC) advertising. Consistent with these higher budgets, I find that post-launch advertising effectiveness is better as unpredicted abnormal approval returns are higher, particularly for detailing (versus DTC). Overall, this study suggests that information flows from the capital market's initial perceptions at new product introduction play an important role in subsequent marketing decisions in the product market.
520 $a [Essay 2].
520 $a While the pharmaceutical firms rely heavily on new product (i.e., drug) development, their marketing decisions take a considerable time even after a new drug is successfully developed. Recently, pharmaceutical firms tend to increase the marketing plan window which stretches three or more years ahead, deploying the drug potential with more efficient marketing functions. This paper examines whether the predicted probability of new drug development success during the development stage (1) reduces the delay in launching the newly developed drug after the drug is approved by FDA and (2) enhances post-launch advertising effectiveness on sales performance. Our analysis consists of the following three steps. First, the predicted probability of new drug development success at the beginning of the third clinical trials phase is estimated based on a hierarchical Bayesian probit model. Next, the analysis from a hierarchical Bayesian proportional hazard model reveals that new drugs with a higher predicted probability of development success are less delayed in launching the drugs in the market after FDA approval. Finally, I find that post-launch advertising effectiveness is greater for a drug with a higher development success probability and this relation is more pronounced when market launch of the drug is less delayed. Overall, our analyses suggest that the expected success probability or failure risk of drug development has important implications for post-development success in launching and marketing for the newly developed drug.
590 $a School code: 0183.
650 4 $a Marketing. $3 173043
650 4 $a Economics. $3 172164
650 4 $a Finance. $3 189642
690 $a 0338
690 $a 0501
690 $a 0508
710 2 $a Purdue University. $b Management. $3 630097
773 0 $t Dissertation Abstracts International $g 77-03A(E).
790 $a 0183
791 $a Ph.D.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3734510

筆 0 讀者評論

多媒體

多媒體檔案
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3734510

評論

新增評論分享你的心得

Export

取書館別